Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TARBP2 | Q15633 | 4/20 | 0.32 |
| ▸ | FBP1 | P09467 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9917050 | 0.82 | HCAR2 (0.39) | HCRTR1HCRTR2KDM1AGRIA1GRIA3 | |
| SCHEMBL17162356 | 0.81 | HCRTR1 (0.35) | HCRTR1HCRTR2KDM1AGRIA1GRIA3 | |
| SCHEMBL17162432 | 0.80 | NPSR1 (0.45) | ALDH1A1HPGDTARBP2FBP1 | |
| SCHEMBL18781940 | 0.79 | HCRTR1 (0.39) | HCRTR1HCRTR2KDM1AGRIA1GRIA3 | |
| SCHEMBL18781937 | 0.78 | HCRTR1 (0.38) | HCRTR1HCRTR2KDM1AGRIA1GRIA3 | |
| SCHEMBL2839466 | 0.77 | HCAR2 (0.41) | HCRTR1HCRTR2HCAR2ALDH1A1TSHR | |
| SCHEMBL4675656 | 0.74 | KDM4E (0.51) | HPGD | |
| SCHEMBL1027753 | 0.74 | ALDH1A1 (0.39) | KDM1AGRIA1GRIA3HCAR2ALDH1A1 | |
| SCHEMBL287238 | 0.73 | ALDH1A1 (0.33) | KDM1AGRIA1GRIA3HCAR2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL19119222 | 0.71 | PDE4B (0.33) | KDM1AGRIA1GRIA3HCAR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3781575-A1 | MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS | Ascentage Pharma (Suzhou) Co., Ltd. (CN) | 2021-02-24 | — | — | EP | disclosed |
| WO-2020151738-A1 | MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2020-07-30 | — | — | WO | disclosed |
| US-9605007-B2 | 2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides | PFIZER INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20120015958-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | N.V. ORGANON (NL) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015958-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | NPC1, ABCB11, NPC1L1 | HCRTR1 785/4885HCRTR2 879/4885KDM1A 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.